FDA adds vision loss warning to all GLP-1 drugs

https://www.drugwatch.com/news/2026/11/09/fda-adds-vision-loss-warning-to-all-glp-1-drugs/

I have included some key paragraphs here:

The U.S. Food and Drug Administration now requires all GLP-1 medications, such as Ozempic, Wegovy, Mounjaro and Zepbound, to include a warning about a rare eye condition that may cause permanent vision loss. The agency shared this update on Nov. 9.
Non-arteritic anterior ischemic optic neuropathy (NAION) may happen when blood flow to the front of the optic nerve decreases. This usually leads to sudden, painless vision loss in one eye, and the damage is usually permanent.

The FDA began investigating this issue after a July 2024 study in JAMA Ophthalmology linked semaglutide, the active ingredient in Ozempic and Wegovy, to NAION. The agency pointed out some limitations in the study but said the results deserved more attention.

The FDA reviewed 126 studies involving over 134,000 people. NAION was not common, but it happened more often in people who took GLP-1 medications. There were about 6 cases per 100,000 people each year for those on GLP-1 drugs, and about 4 cases per 100,000 people for those taking a placebo or another diabetes medicine.

Patients who have already experienced NAION should discuss with their doctor whether to keep taking their GLP-1 medication. If someone has had NAION in one eye, they are at higher risk of developing it in the other eye.
The agency recommends that doctors quickly refer patients with suspected NAION to an ophthalmologist. Providers should also consider stopping the GLP-1 drug unless the benefits clearly outweigh the risks.

Author: satellitevagabond